DDInter1376 DDInter642
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
Enfortumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lumacaftor
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Enfortumab vedotin may lead to a major life threatening interaction when taken with Fingolimod
Enfortumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib